Purinoceptor activation of chloride transport in cystic fibrosis and CFTR-transfected pancreatic cell lines.
The regulation of chloride efflux from cystic fibrosis pancreatic adenocarcinoma cells (CFPAC-1) and wild-type CFTR-transfected CFPAC-1 cells (TPAC) was compared. Forskolin (10 microM) stimulated chloride efflux from the corrected TPAC cells but not from CFPAC-1 cells. Chloride efflux from both cell types was activated by thapsigargin (0.5 microM). The nucleotides ATP and UTP and the non-hydrolyzable ATP analogue, adenosine 5'-O-(3-thio) triphosphate (ATPgammaS), stimulated chloride efflux from both cell types. None of the other P2 purinoceptor agonists investigated elicited a response. The order of potency was ATP > or = UTP > or = ATPgammaS. Adenosine (10-100 microM) activated choride efflux from the TPAC but not the CFPAC cell line with no increase in intracellular cyclic AMP. Small but statistically significant inhibitions of the adenosine-(50 microM)-stimulated increase in chloride efflux were elicited by the A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (CPX, 100 nM) and the A2 receptor antagonist 3,7-dimethyl-1-propylargylxanthine (DMPX, 10 microM). The A2A receptor antagonist 8-(3-chlorostyryl)caffeine (CSC, 100 nM) had no significant effect. These results provide evidence for the regulation of chloride efflux by P2Y2 purinoceptors in genetically-corrected and CF pancreatic cell lines. Studies with adenosine receptor antagonists indicate some possible involvement of A1 and A2 (but not A2A) receptors in the adenosine stimulation of chloride efflux, but the relatively small effects of the inhibitors coupled with lack of increase in cyclic AMP and a response only in the CFTR-transfected cells also suggests a possible direct effect of adenosine on CFTR.
O'Reilly
C M
CM
Department of Pharmacology, University College Dublin, Belfield, Ireland.
O'Farrell
A M
AM
Ryan
M P
MP
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D002460:Cell Line; D018118:Chloride Channels / Q000187:drug effects / Q000378:metabolism*; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D003550:Cystic Fibrosis / Q000235:genetics / Q000378:metabolism*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D010179:Pancreas / Q000166:cytology / Q000378:metabolism*; D058913:Purinergic Agonists; D011983:Receptors, Purinergic / Q000235:genetics; D019284:Thapsigargin / Q000494:pharmacology; D014162:Transfection; D014544:Uridine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology
C505032:CFTR protein, human; D018118:Chloride Channels; D004791:Enzyme Inhibitors; D058913:Purinergic Agonists; D011983:Receptors, Purinergic; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D005576:Colforsin; D019284:Thapsigargin; D000255:Adenosine Triphosphate; D000242:Cyclic AMP; D014544:Uridine Triphosphate